Ethris Overview

  • Founded
  • 2009
Founded
  • Status
  • Private
  • Employees
  • 27
Employees
  • Latest Deal Type
  • Series A
  • Investors
  • 3

Ethris General Information

Description

Developer of RNA-based therapies created to to treat patients with respiratory disorders. The company's novel RNA-modification technology creates stable and non-immungenic messenger RNA (SNIM-RNA) molecules that are suited for use in protein-replacement therapies, thus enabling healthcare providers to treat monogenic genetic diseases, including personalized vaccines to treat tumors.

Contact Information

Website
www.ethris.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Primary Office
  • Semmelweisstr. 3
  • 82152 Planegg
  • Germany
+49 089 00000000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Ethris Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Early Stage VC (Series A) 01-Dec-2011 Completed Generating Revenue
1. Grant 06-May-2011 Completed Generating Revenue
To view Ethris’s complete valuation and funding history, request access »

Ethris Executive Team (6)

Name Title Board Seat Contact Info
Carsten Rudolph Ph.D Co-Founder & Chief Executive Officer
Christian Plank Ph.D Co-Founder, Chief Technology Officer, Managing Director & CSO
Thomas Langenickel Ph.D Chief Medical Officer
You’re viewing 3 of 6 executive team members. Get the full list »

Ethris Board Members (6)

Name Representing Role Since
Gerd Maass Ph.D Ethris Board Member 000 0000
Justin Duckworth HS LifeSciences Board Member 000 0000
Karsten Henco Ph.D HS LifeSciences Board Member 000 0000
Thomas Chalberg Ph.D Ethris Board Member 000 0000
You’re viewing 4 of 6 board members. Get the full list »

Ethris Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Ethris Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
HS LifeSciences Venture Capital Minority 000 0000 000000 0
OrbiMed PE/Buyout Minority 000 0000 000000 0
Bundesministerium für Bildung und Forschung Government 000 0000 000000 0
To view Ethris’s complete investors history, request access »